BILAN ETAPE Anglais internet - chu-toulouse.fr · epidemiological, human and social sciences. Furthermore, they should be conducted together with European and international actions

Progress report2 years after

U

Gérontopôle locations

CLINICAL DEPARTMENT

CLINICAL RESEARCH CENTRE - AGING INSTITUTE

AGING INSTITUTE

Progress Report2 years after

Gérontopôle de Toulouse

– policy development, through the Institut duVieillissement (Ageing Institute), concerninglack of independence and based on anepidemiological research: the Gérontopôlehas conducted the GuidAge (1) and MAPT (2)studies on prevention of Alzheimer’s diseaseand cognitive decline.

– research related to geriatric network supportin connection with nursing homes for elderlydependent persons: the Gérontopôle hascreated the REHPA (3) research network. Itenables to improve care procedures for oldpeople with a better screening of dementia inEHPAD institutes, thus avoiding inappropriatehospital admission.

The Toulouse Gérontopôle has conductedhigh variety and quality actions throughfundamental research, prevention andmodelling of elderly persons’care procedures.It shows the purpose of today’s organizationdedicated to a still insufficiently explored area:gerontology.

In 2007, in view of the public health issuesrelated to life extension, the Ministry of Healthcreated in France and on a trial basis, anexpertise and gerontology research organizationon international standards. The aim was toorganize in a unique framework, all of themedical, pharmacological, epidemiological andsociological research in the field of ageing. TheToulouse CHU - Centre Hospitalier Universitaire(University Hospital Centre), with its longexperience in this matter, was chosen to supportthis project: the Gérontopôle was created.

After only two years existence, theGérontopôle has achieved its assignmentscommitted in 2007 and has proven theusefulness of such a structure dedicated toorganizing research in gerontology, and moreso towards research on Alzheimer’s disease.

The Gérontopôle sets up research programsand actions with regards to:– clinical research and trials on promising

molecules: the Gérontopôle coordinates theCeNGEPS - Centre National de Gestion desEssais de Produits de Santé (National Centrefor Management of Trials on Health Products)Alzheimer’s disease network. Furthermore, italso coordinates the study on biomarkersresearch associated to memory disorders.

Annie PodeurMinistry of Health and SportsHospitalization and care planning Department

FOREWORD

PROGRESS REPORT - 2 YEARS AFTER - GERONTOPOLE - TOULOUSE UNIVERSITY HOSPITAL 3

(1) Phase III trial concerning the efficiency of Ginkgo Biloba on the impact and delay of appearance of an Alzheimertype dementia.

(2) Multi-domain Alzheimer Preventive Trial

(3) Research network, identification of specific problems related to old age care in EHPAD

4 PROGRESS REPORT - 2 YEARS AFTER - GERONTOPOLE - TOULOUSE UNIVERSITY HOSPITAL

actions are coordinated by the Gérontopôle andare the result of a few decades (two generations)of work, as mentioned by the Professor JoëlMénard in his preface.

The Gérontopôle contributed to animportant increase, on behalf of France, in theconception, the methodology and theexecution of major therapeutic trials. They aimto modify the progression of Alzheimer’sdisease assisted by innovative therapeutics:immunotherapy, gamma-secretase and beta-secretase inhibitors (BACE), for example.France’s involvement will increase significantlywithin the next years. With the assistance ofour Deans, the Gérontopôle was able to createan Institut du Vieillissement in the heart of theToulouse-Purpan Medical College. This iswhere the major GuidAge and MAPT preventiontrials are conceived, followed up andorganized. They were the first ever undertakenin Europe whilst major trials were carried out inthe United States. It is from these majorrandomised double-blinded trials, conductedover many years and involving an importantnumber of subjects, that significantinformation will be recorded with regards to theway a simple memory complaint becomes acognitive decline, and eventually changes intoAlzheimer’s disease. The associated biobankswill be of considerable help to validatebiomarkers.

The Gérontopôle has executed itsassignments: be of service to the geriatric fieldand develop clinical research in Alzheimer careunits and in institutes for elderly dependentpeople from the PHRC PLASA networks(bringing together 20 University Hospitals and30 General Hospitals). This work has also beenapplied to the REHPA network and enabled tounite 240 institutes eager to conduct researchprograms in EHPAD. Indeed, whereas these

The Toulouse Gérontopôle is a sign of trust.It represents an assignment born by a teamcommitted without fear to the scope of works.Today, the major risk in clinical research is toleave a predefined program unfulfilled. Thereare many likely reasons for this: numerousdemands, heavy work, obstructions andobligations in administrative, psychological,financial, human and scientific terms. Whyaccept all these difficulties, when bonuses areso remote and uncertain?

Yet the worst thing is to start a project andleave it unattended. What energy, how manyworking hours, how much financial investmentare spent in France and in many othercountries, to conceive a research program, tostart it up and then to give it up whenunavoidable hardships and outside requestscome up? It is our duty to get together whendifficulties begin, in order to overcome themand allow each actor, whatever his part in theproject, to be rightly thanked and rewardedupon its successful outcome.

This is why, under the impulse of theGeriatric Gerontology Centre teams of theToulouse CHU (University Hospital), of theINSERM U558 unit, of the University Departmentof Epidemiology, Health Economy and PublicHealth, as well as of a number of CHU teams, wewere able to set up the Gérontopôle action plan,as forecasted. It was owed to the contribution ofregional networks (memory consultations,geriatric services, EHPAD, Southern FranceCMRR Federation), national networks (PHRC,REAL FR, PLASA, CeNGEPS Alzheimer network ofthe CMRR Federations, REHPA – researchnetwork in EPHAD institutions), Europeannetworks (EADC – European Alzheimer’s DiseaseConsortium, Ictus, AddNeuroMed, E-ADNI) andinternational networks (University of NewMexico in USA, IAGG). An important number of

Bruno Vellas


places shelter the most frail and dependentelderly persons, clinical research has beenlacking in them. The PHRC, REAL FR and PLASAcontributed to the definition of indicators forthe Presidential Plan on Alzheimer’s disease bya better long-term knowledge of this disease.Thirty international publications were based onthese works.

The ONRA - Observatoire National de laRecherche sur la maladie d’Alzheimer (NationalCommission for Research on Alzheimer’sdisease), entrusted to the Gérontopôle,updates these indicators and lists theAlzheimer’s disease research teams in France,their scientific works and allows an access forall teams to the related therapeutic trials.Under the impulse of our General Manager, animportant cultural program is being undergoneand will accompany the Gérontopôle actionplan in all its aspects. Today the existence ofthe Gérontopôle is due to high expertise andcontinuous efforts of all involved teams, totheir important works and to their passion inthe struggle against Alzheimer’s disease. It alsoexists owing to the constant confidence of ourdifferent national and regional authorities:French Ministry of Health, GeneralManagement of ARH – Agences Régionales del’Hospitalisation (Regional Agencies forHospitalization) and of the CHU – CentreHospitalier Universitaire (University Hospital)and the Deans of the two Toulouse MedicalColleges.


SYNTHESIS

Since a number of years, the CHU – Centre Hospitalier Universitaire(University Hospital Centre) – of Toulouse is engaged in a global approachconcerning the care of elderly people. The geriatric centre has beenorganized together with those involved in internal and external geriatriccare throughout the southwest region of France. This interrelatedexpertise stimulates communication and research at a regional, nationaland international level. The creation of the Toulouse Gérontopôle, byProfessor Bruno Vellas, is therefore a logical and legitimate continuation.

The demographic aging trends will continuein the future and it becomes necessary to

develop research in geriatrics and gerontology.Health, social, political and economical issuesare the main challenge in this field.

Amongst them, Alzheimer’s disease and itsassociated disorders are a priority. Theirprevalence is increasing with 860 000 personssuffering from these disorders and 225 000new cases observed each year. The impact onfamily and community is important: it accountsfor 70 % of the admission in special carefacilities and 72 % of the applications for the“Allocation Personnalisée à l’Autonomie” (aPublic Fund for Personal Autonomy). Its annualcost is estimated at 9.9 billion €, 55% of whichis directly born by families.

Research programs must be based on amultidisciplinary approach involvingdifferent specialties: fundamental, clinical,epidemiological, human and social sciences.Furthermore, they should be conductedtogether with European and internationalactions already undertaken in this area.

This is why, reflecting the actual needs ofthe elderly, the Toulouse Gérontopôle was

created on February 5th, 2007, in response to anengagement of French ministers XavierBertrand and Philippe Bas. Its assignment isstructured around three types of actions:- access to diagnosis, to innovative therapy

and to clinical research for elderly and frailpersons often excluded from theseprograms,

- implementation of the Institut duVieillissement (Ageing Institute) to developand validate health enhancement andprevention programs for healthy elderlypersons,

- dedication towards the geriatric network inorder to develop clinical research for elderlydependent persons.

The aim of the Gérontopôle is to create adynamic organization between the clinicalactivities of the Toulouse CHU GeriatricsGerontology centre and the research works ofthe Ageing team of the INSERM - InstitutNational de la Santé et de la RechercheMédicale (National Health and MedicalResearch Institute) U558 unit. This enables tofoster multidisciplinary research associated toquality care. It is born by the Toulouse CHUGeriatrics Gerontology centre (Professor BrunoVellas), in joint collaboration with the InsermU558 unit “Risk, chronic diseases, handicap”

(Doctor Hélène Grandjean), and getsmethodological support from theEpidemiological and Public Health Departmentof the Toulouse CHU (Professor Alain Grand) atdifferent research levels.

ACTION N° 1Access to diagnosis, to innovative therapy andto clinical research for elderly and frail persons

One of the main issues of the struggleagainst Alzheimer’s disease is theimplementation of major therapeutic trials.There are currently no structured researchplans to lead these trials, such as those carriedout for other pathologies like cancer.

Furthermore, as opposed to easternEuropean countries, Asia or even WesternEurope (Germany, Spain), a decline in researchactivity in major pharmaceutical laboratories inFrance has been registered. The Gérontopôleset up a certain number of actions to improvetherapeutic trials recruitment:

• organizing research on a local and nationalbasis with:

organization of therapy research within theToulouse CMRR - Centre Mémoire de Ressourceet de Recherche (Memory Resource andResearch Centre) as well as the memoryconsultations in the Midi-Pyrénées region: setup of clinical research consultation,recruitment and coordination of clinicalresearch technicians in different regions,organization of telemedicine sessions, andcreation of a newsletter intended forGérontopôle medical teams, regional memoryconsultations and general practitionersnetwork,

set up and management, on a national basis,of the CeNGEPS - Centre National de Gestiondes Essais des Produits de Santé (NationalCentre for Management of Trials on HealthProducts) “Alzheimer” network of the CMRRorganization since July 2008,

national coordination of 10 therapeutic trialson promising molecules that have a potentialdisease modifying effects on mechanisms andevolution of Alzheimer’s disease:

With all these efforts, we have registered animportant increase of the number of subjectsrecruited in 2008 for therapeutic trials. InToulouse, 55 patients were included in phase IIor III of the therapeutic trials in 2008 (against30 in 2007), and 41 patients were randomised(against 24 in 2007). On a national level, anddue to the CeNGEPS network, the number ofpatients included in phase II or III of thetherapeutic trials raised considerably from2007 to 2008. It passed from 149 to 225patients included and from 113 to 176 patientsrandomised, progressing by about 50%. Onemust add to these figures, the patientsincluded in industrial promotion trials onbiomarkers research and prevention trialsjointly conducted with industry (respectively161 and 184 patients in 2008). The aim is toreach by 2012, 400 to 500 patients includedevery year in phase I, II or III concerningAlzheimer’s disease. This could be done byintensifying the above mentioned actions andby increasing the number of recruiting centresinvolved in the CeNGEPS network, at a regionaland national level.

The Gérontopôle develops proper research onthe methodology used on the Alzheimer’sdisease therapeutic trials. This includes, in

2007-2008 Therapeutic trials

Phase II• Alpha secretase modulator,

Exonhit (IIa)• Lecozotan, Wyeth (IIb)

Phase III• Alzhemed, Neurochem• Rosiglitazone, GSK• Gamma secretase inhibitor, Lilly

2009

Phase II

• Immunoglobulin, Baxter (IIb)• Histaminic antagonistic H3,

Servier (IIa)• Nicotinic agonist, Roche (IIb)• Monoclonal antibody, Lilly (IIb)

Phase III • Dimebon, Mediaviation



particular, the coordination of internationalmeetings combining experts from differentbackgrounds (academic, industrial, agencies)implied in the trials’ concept. This enables toengage a methodological analysis on Alzheimer’sdisease’s new trials outline and the criteria ofjudgment to be taken into account, particularlythe position of biomarkers. These works lead tothe publication of recommendations in theLancet Neurology in 2007 and 2008.

Through a quantity and quality approach, wecoordinate a multidisciplinary research,specifically dedicated to the study of reasonsfor involvement and support in a therapeutictrial (ACCEPT study). The outcome will allow usto understand more easily why patients acceptto attend trials and to distinguish those whomight reject the offer and finally to find meansto brush away the dread of acceptance.Examination of these reasons will permit abetter fitting of the concept and managementof therapeutic trial plans. This study will thenbe presented to general practitioners, and topatients suffering from Alzheimer’s disease andtheir families. It will enable a better definitionof the limits to participation in clinical andtherapy research.

Within the framework of Step 41 of thePresidential Plan on Alzheimer’s disease, wewere assigned to put information on the ONRA- Observatoire National de la Recherche sur lamaladie d’Alzheimer (National Commission forResearch on Alzheimer’s disease) websiterelated to all of the research currentlyconducted in France, including therapeutictrials undergone in the country. With this actionpatients and their families have access totherapy innovation and clinical research. Thiswork should ease information circulation andinclusion in research protocols for patients.

• Involvement in a number of trials:

the carrying out of 4 studies concerningbiomarkers for Alzheimer’s disease:

• European study AddNeuroMed: “Research ofbiological markers associated to memorydisorders”.

• E-ADNI study: “European Alzheimer’sDisease Neuroimaging Initiative”

• EHT AD/002 study: “Blood diagnostic test ofAlzheimer’s disease”, Exonhit

• ROSAS Study: “Search of proteic biomarkersin Alzheimer’s disease”, Servier

At the same time as therapeutic trials arebeing conducted for Alzheimer’s disease, theGérontopôle recently develops researchprograms on sarcopenia (age-related loss ofmuscle mass) and frailty with in particular,identification of frailty biomarkers (05.04.NRCstudy “Identification of frailty biomarkers inelderly persons”, Nestlé), and involvement in aPhase IIa trial on treatment of sarcopenia(MK0773-005 study “Phase IIa clinical study, atrandom against placebo, assessing theefficiency and acceptance of MK-0773 fromsarcopenia suffering patients”, MSD).

ACTION N° 2Implementation of the Institut du Vieillissementwhich will contribute to develop and validateprograms for health enhancement andprevention for elderly persons in good health

The Gérontopôle created the Institut duVieillissement in the Toulouse city centre,giving a better access to elderly personsunconcerned by hospital care:• the Toulouse Purpan Medical College

(situated Allées Jules Guesde) is runningsince summer 2008 (official opening onNovember 6th, 2008). It is dedicated topromoting health and training. A secondperiod of works is planned in 2009.

• the La Grave centre, will open in April 2009. Itwill be dedicated to clinical research,carrying out prevention trials, Step III trials,and follow up of groups established by theFondation de la Coopération ScientifiqueAlzheimer (the Alzheimer ScientificCooperation Foundation).

Two major prevention trials are currentlymanaged by the Gérontopôle:

– the GuidAge study recruited 2800 elderlypeople declaring memory disorder. Thesepersons are divided at random into two groupsand are given either Ginkgo Biloba, either a


placebo, during 5 years. This study is the firstmajor trial on prevention of Alzheimer’s diseasein Europe and it will bring importantinformation with regards to the way initialcomplaint becomes Alzheimer’s disease.Furthermore, biological samples will becollected during the survey. This will permit toidentify biomarkers that will be useful inprognosis and diagnosis of the disease. Thelast participant involved in the survey willundergo his 5-year end-of study consultation inOctober 2009. The results of this study will beavailable beginning 2010.

– the Gérontopôle, operating with majorAmerican teams, validates a multi-domainintervention program associating nutrition,cognitive stimulation, physical exercise,detection of sensory disorders and support ofcardiovascular diseases. This intervention istested as part of the MAPT (Multi-domainAlzheimer Preventive Trial) study, fostered bythe Toulouse CHU. This study’s aim is to assessthe impact of omega-3 fatty acid and of themulti-domain intervention program on thecognitive decline on 1.200 frail elderly subjectsduring a 3-year period. Recruitment is currentlyunderway in Toulouse, Bordeaux, Limoges andMontpellier. Three hundred and six old peoplewere recruited by 10th March 2009. On average,45 contributors are included every month sincethe opening of the 4 centres (October 2008).

Actions related to health promotion areorganized in a joint effort with the SeniorCitizen’s University of Social Sciences ofToulouse, Pension Funds and Toulouse towncouncil. They offer the possibility for elderlypeople to receive training concerningprevention for age-related pathologies.

The Institut du Vieillissement is a place fordiscussion and professional training.Furthermore, it hosts the IAGG (InternationalAssociation of Gerontology and Geriatrics)headquarters from 2009 to 2013.

ACTION N° 3The Gérontopôle is dedicated to service for thegeriatric network in order to develop clinicalresearch for elderly and dependent persons.

The actions are developed around threemajors issues: assessment of the care given tothe elderly persons suffering from Alzheimer’sdisease and identification of the specificproblems concerning care of old people livingin EHPAD - Etablissements d’Hébergementpour Personnes Agées Dépendantes (Institutesfor Elderly Dependent Persons). The last issueis related to assessment of geriatric network.This is done through evaluation of the geriatricmobile teams’ performances and of the firstmobile team concerned by severe dementia,set up by the Gérontopôle on the 1st January2008.

More than 600.000 elderly subjects live innursing homes and report many pathologies.However, research is almost completely lackingin these organizations. The Gérontopôle hasset up a network called REHPA - Recherche enEtablissement d’Hébergement pour PersonnesAgées (Research in Institute for ElderlyPersons). Its aim is to identify clinical problemsthat could benefit from added research. Thenetwork currently involves 240 homes inFrance, of which 178 are situated in the Midi-Pyrénées region. The primary data availablefrom the REHPA survey reveals that 50% ofAlzheimer’s disease cases were not detected inEHPAD. One of the outlooks of the network is toassess whether there is an advantage in anautomatic tracking of dementia inside nursinghomes, through pluri-disciplinary consultationmeetings related to the hospital admission rateof elderly people living in EHPAD.

The first Alzheimer’s disease intensive careunit was created in Toulouse in 1996, with threemajor assignments: diagnosis of difficult cases,management of acute complications andtreatment of acute associated diseases. Theunit receives an increasing number of patientsreporting severe behaviour disorders, such asaggressiveness. At this point, a new hospitaladmission is then often observed. For thisreason, the Gérontopôle set up the first mobileteam concerned by severe dementia. Made up


SCIENTIFIC WORKS(2007-2008)

The global actions of the Gérontopôle lead tothe publication of 61 articles in internationaljournals registered on Medline in 2007 and2008 (compared to 35 in 2005 and 2006).

Five major publications:

• Vellas B, Black R, Thal L, Fox NC, Daniels M,McLennan G, Tompkins C, Leibman C,Pomfret M, Grundman M; for the AN1792(QS-21)-251 Study Team. Long-Term Follow-Up of Patients Immunized with AN1792:Reduced Functional Decline in AntibodyResponders. Current Alzheimer Research,2009 (in press)

• Vellas B, Andrieu S, Sampaio C, Coley N,Wilcock G; European Task Force Group.Endpoints for trials in Alzheimer's disease: aEuropean task force consensus. LancetNeurol. 2008 May; 7(5):436-50

• Andrieu S, Ousset PJ, Coley N, Ouzid M,Mathiex-Fortunet H, Vellas B; GuidAge studyGROUP : GuidAge Study: A 5-Year DoubleBlind, Randomised Trial of EGb 761 for thePrevention of Alzheimer's Disease in ElderlySubjects with Memory Complaints.I. Rationale, Design and Baseline Data. CurrAlzheimer Res. 2008 Aug;5(4):406-15.

• Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A.Dementia Prevention: MethodologicalExplanations for Inconsistent Results.Epidemiol Rev. 2008 Sep 8.

• Vellas B, Andrieu S, Sampaio C, Wilcock G;European Task Force group. Disease-modifying trials in Alzheimer's disease: aEuropean task force consensus. LancetNeurol. 2007 Jan; 6(1):56-62. Review

of a practitioner and a nurse, this teammanaged 184 subjects (41,3%) out of the 445patients admitted in the Alzheimer’s diseaseintensive care unit from January to November2008. Assessment of the mobile team’sperformances is being undergone. Othersimilar actions will be prepared in 2009: suchas a cognitive-behaviour unit scheduled foropening during the first half-year according tothe French presidential program on Alzheimer’sdisease.

The Gérontopôle continues research programsconcerning patient care for those affected byAlzheimer’s disease subject of 42 internationalpublications and that allows us to provideindicators concerning the development of thedisease for the Presidential Plan:

– PHRC 1998: “Care network for Alzheimerpatients and predicted factors for admissionin related facilities. Multi-centric surveynetwork” and PHRC 2001 “Multi-centricsurvey concerning the reel impact ofcholinesterase inhibitors in Alzheimer’sdisease”: 686 patients followed up during4 years

– PHRC 2003: “End of life and Alzheimer’sdisease. ALFINE study”: 100 patientsfollowed up during 2 years

– European project: “ICTUS study: The impactof treatment with acetyl-cholinesteraseinhibitors on Europeans with Alzheimer’sdisease”: 1385 patients followed up during2 years

– PHRC 2002 and 2006: “PLASA study:Alzheimer’s disease care and specificassistance program”: intervention studyassessing standard care, 1121 patientsfollowed up during 4 years

Within the framework of the PresidentialPlan, the Gérontopôle has also written twodocuments for the DGAS - Direction Généralede l’Action Sociale (National Social ServicesDepartment): a reference book on Alzheimer’sdisease care units in EHPAD and a journal onrespite facilities.


During the last two years, theGérontopôle set up committed assignmentsin major, fast-growing fields. It is nowbecome an outstanding organization dedi-cated to care, health development and cli-nical research. We are able to conceiveoriginal research programs. Reinforcementof clinical research means to increase quan-tity and inclusion rate in new drug and pre-vention trials is another of our tasks. Wealso organize regional, national andEuropean research networks and developpartnership with international researchteams. The build-up of research activitieshas led to an increase of scientific works.

Complementary financial support Amount granted

- Funds from PHRC 2008 – Programme hospitalier de recherche clinique (NationalHospital Program for Clinical Research): “Prevention of cognitive decline: impact of amulti-domain stimulation and an omega-3 fatty acid complement. MAPT study”

- Funds from ARH – Agence Régionale d’Hospitalisation (Regional Agency forHospitalization): ARC - Attaché de Recherche Clinique (Clinical Research Assistant) jobs

294 000 €

120 000 €

- Funds from DGS - Direction Générale de la Santé (National Health Department):. ONRA – Observatoire National de la Recherche sur la maladie d’Alzheimer (NationalCommission for Research on Alzheimer’s disease). Develop a communication tool for circulation of the Care and Aide Program for Alzheimer patients: creation of a follow-up record for general practitioners”

145 000 €

40 000 €

- Funds from DGAS - Direction Générale de l’Action Sociale (National Social ServicesDepartment): “Drafting of references on Alzheimer’s disease care units in EHPAD and respite facilities”

60 000 €

- Funds from INPES – Institut National de Prévention et d’Education pour la Santé(National Institute for Health Prevention and Education) tender from IReSP - Institut deRecherche en Santé Publique (Public Health Research Institute): ACCEPT study

- Funds from CeNGEPS - Centre National de Gestion des Essais des Produits de Santé(National Centre for Management of Trials on Health Products)

100 000 €

263 000 €

- Funds from industrial partnerships:. Pierre Fabre laboratory (MAPT study). Exonhit laboratory (MAPT study). Nestlé laboratory (biomarkers on frailty) . Servier laboratory (biomarkers on Alzheimer’s disease)

2 100 000 €220 000 €

91 540 €

520 430 €- Funds from European Commission:. AddNeuroMed study. Ictus study. E-ADNI study

29 516 €90 035 €14 997 €

- Funds from ANR- Agence Nationale de la Recherche (French National Research Agency):MIRAS study (ANR-08-ECS-009-06) 59 696 €

ConclusionFUNDS RECEIVED (2007-2008)

The means granted to the Gérontopôle amountat 345.000 € in 2007 and 2008. This includes the150.000 € granted by the DHOS - Direction del’Hospitalisation et de l’Organization des Soins(Hospitalization and care planning Department)and the 195.000 € granted by the ARH - AgenceRégionale d’Hospitalisation (Regional Agency forHospitalization). Complementary resources havebeen obtained for the set up of the Gérontopôle’saction program.

Call up for grants in 2009:• reply to the PHRC 2009 tender (application

for: 586.000 €)• reply to the joint Aquitaine/Midi-Pyrénées

inter-regional tender (application for:927.720 €)

• reply to the CeNGEPS 2009 tender(application for: 380.000 €)

• reply to the ANR 2009 tender (applicationfor: 312.416 €)

CONTACTSCO

NTA

CTS

Gérontopôle

Professor Bruno [email protected] : 05.61.77.76.49Fax : 05.61.49.71.09

Sophie Gillette, [email protected] : 05.61.77.99.37Fax : 05.61.77.25.93

Communication

Marie-Claude [email protected] : 05.61.77.83.49Fax : 05.61.77.85.21

Website : www.chu-toulouse.frlink : Gérontopôle

Documents

BILAN ETAPE Anglais internet - chu-toulouse.fr · epidemiological, human and social sciences. Furthermore, they should be conducted together with European and international actions